JP2015515989A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015515989A5 JP2015515989A5 JP2015510483A JP2015510483A JP2015515989A5 JP 2015515989 A5 JP2015515989 A5 JP 2015515989A5 JP 2015510483 A JP2015510483 A JP 2015510483A JP 2015510483 A JP2015510483 A JP 2015510483A JP 2015515989 A5 JP2015515989 A5 JP 2015515989A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- independently
- aryl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 84
- 125000006545 (C1-C9) alkyl group Chemical group 0.000 claims description 47
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 47
- 125000000217 alkyl group Chemical group 0.000 claims description 46
- 125000001424 substituent group Chemical group 0.000 claims description 42
- 125000003118 aryl group Chemical group 0.000 claims description 39
- 150000004820 halides Chemical class 0.000 claims description 38
- 125000000623 heterocyclic group Chemical group 0.000 claims description 35
- 201000010099 disease Diseases 0.000 claims description 24
- 208000035475 disorder Diseases 0.000 claims description 23
- 150000003839 salts Chemical class 0.000 claims description 23
- PIGFYZPCRLYGLF-UHFFFAOYSA-N Aluminum nitride Chemical compound [Al]#N PIGFYZPCRLYGLF-UHFFFAOYSA-N 0.000 claims description 22
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 22
- 125000001072 heteroaryl group Chemical group 0.000 claims description 20
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 12
- 102000013814 Wnt Human genes 0.000 claims description 8
- 108050003627 Wnt Proteins 0.000 claims description 8
- 229910052731 fluorine Inorganic materials 0.000 claims description 8
- 125000001153 fluoro group Chemical group F* 0.000 claims description 7
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 6
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 6
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 5
- 230000002159 abnormal effect Effects 0.000 claims description 5
- 125000004193 piperazinyl group Chemical group 0.000 claims description 5
- 125000003386 piperidinyl group Chemical group 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 125000002541 furyl group Chemical group 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 230000011664 signaling Effects 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- 125000002393 azetidinyl group Chemical group 0.000 claims description 3
- 210000000988 bone and bone Anatomy 0.000 claims description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 208000020084 Bone disease Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 206010012289 Dementia Diseases 0.000 claims description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 2
- 206010017533 Fungal infection Diseases 0.000 claims description 2
- 208000019693 Lung disease Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000031888 Mycoses Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 208000015100 cartilage disease Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 230000002538 fungal effect Effects 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 208000036487 Arthropathies Diseases 0.000 claims 1
- 208000012659 Joint disease Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 description 7
- 0 *c1c(*)ncc2c1nc(-c(c1c3)n[n]c1ncc3-c1c(*)*(*)c(*)nc1)[n]2 Chemical compound *c1c(*)ncc2c1nc(-c(c1c3)n[n]c1ncc3-c1c(*)*(*)c(*)nc1)[n]2 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 125000004076 pyridyl group Chemical group 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 208000009575 Angelman syndrome Diseases 0.000 description 1
- 201000000046 Beckwith-Wiedemann syndrome Diseases 0.000 description 1
- GHVDUYGLIBYHHD-UHFFFAOYSA-O C(C1CCCC1)NCc1cc(-c(cc23)c[nH+]c2[nH]nc3-c2nc3ccncc3[nH]2)cnc1 Chemical compound C(C1CCCC1)NCc1cc(-c(cc23)c[nH+]c2[nH]nc3-c2nc3ccncc3[nH]2)cnc1 GHVDUYGLIBYHHD-UHFFFAOYSA-O 0.000 description 1
- ADENEOMUUQJZFH-UHFFFAOYSA-N C(c1ccccc1)NCc1cc(-c2cc(c(-c3nc(ccnc4)c4[nH]3)n[nH]3)c3nc2)cnc1 Chemical compound C(c1ccccc1)NCc1cc(-c2cc(c(-c3nc(ccnc4)c4[nH]3)n[nH]3)c3nc2)cnc1 ADENEOMUUQJZFH-UHFFFAOYSA-N 0.000 description 1
- LQGMKRPMUWLRKC-YFVJMOTDSA-N CCCCC(N/C(/C)=C/C(/c(cc12)cnc1[nH]nc2[IH]1=Nc(ccnc2)c2N1)=C\N=C)=O Chemical compound CCCCC(N/C(/C)=C/C(/c(cc12)cnc1[nH]nc2[IH]1=Nc(ccnc2)c2N1)=C\N=C)=O LQGMKRPMUWLRKC-YFVJMOTDSA-N 0.000 description 1
- 208000026010 Caudal duplication Diseases 0.000 description 1
- 101100317380 Danio rerio wnt4a gene Proteins 0.000 description 1
- 208000028506 Familial Exudative Vitreoretinopathies Diseases 0.000 description 1
- 206010061159 Foot deformity Diseases 0.000 description 1
- 208000008875 Fuhrmann syndrome Diseases 0.000 description 1
- 101000814371 Homo sapiens Protein Wnt-10a Proteins 0.000 description 1
- 101000770799 Homo sapiens Protein Wnt-10b Proteins 0.000 description 1
- 101000781981 Homo sapiens Protein Wnt-11 Proteins 0.000 description 1
- 101000781950 Homo sapiens Protein Wnt-16 Proteins 0.000 description 1
- 101000804728 Homo sapiens Protein Wnt-2b Proteins 0.000 description 1
- 101000804792 Homo sapiens Protein Wnt-5a Proteins 0.000 description 1
- 101000804804 Homo sapiens Protein Wnt-5b Proteins 0.000 description 1
- 101000855002 Homo sapiens Protein Wnt-6 Proteins 0.000 description 1
- 101000855004 Homo sapiens Protein Wnt-7a Proteins 0.000 description 1
- 101000814380 Homo sapiens Protein Wnt-7b Proteins 0.000 description 1
- 101000814350 Homo sapiens Protein Wnt-8a Proteins 0.000 description 1
- 101000650149 Homo sapiens Protein Wnt-8b Proteins 0.000 description 1
- 101000650117 Homo sapiens Protein Wnt-9a Proteins 0.000 description 1
- 101000650119 Homo sapiens Protein Wnt-9b Proteins 0.000 description 1
- 101000781955 Homo sapiens Proto-oncogene Wnt-1 Proteins 0.000 description 1
- 101000954762 Homo sapiens Proto-oncogene Wnt-3 Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 201000010769 Prader-Willi syndrome Diseases 0.000 description 1
- 206010049422 Precancerous skin lesion Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102100039461 Protein Wnt-10a Human genes 0.000 description 1
- 102100029062 Protein Wnt-10b Human genes 0.000 description 1
- 102100036567 Protein Wnt-11 Human genes 0.000 description 1
- 102100036587 Protein Wnt-16 Human genes 0.000 description 1
- 102100035289 Protein Wnt-2b Human genes 0.000 description 1
- 102100035331 Protein Wnt-5b Human genes 0.000 description 1
- 102100020732 Protein Wnt-6 Human genes 0.000 description 1
- 102100020729 Protein Wnt-7a Human genes 0.000 description 1
- 102100039470 Protein Wnt-7b Human genes 0.000 description 1
- 102100039453 Protein Wnt-8a Human genes 0.000 description 1
- 102100027542 Protein Wnt-8b Human genes 0.000 description 1
- 102100027503 Protein Wnt-9a Human genes 0.000 description 1
- 102100027502 Protein Wnt-9b Human genes 0.000 description 1
- 208000022617 SERKAL syndrome Diseases 0.000 description 1
- 206010072610 Skeletal dysplasia Diseases 0.000 description 1
- 206010040869 Skin hypoplasia Diseases 0.000 description 1
- 206010047486 Virilism Diseases 0.000 description 1
- 101150010310 WNT-4 gene Proteins 0.000 description 1
- 101150019524 WNT2 gene Proteins 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 102000052547 Wnt-1 Human genes 0.000 description 1
- 102000052556 Wnt-2 Human genes 0.000 description 1
- 108700020986 Wnt-2 Proteins 0.000 description 1
- 102000052549 Wnt-3 Human genes 0.000 description 1
- 102000052548 Wnt-4 Human genes 0.000 description 1
- 108700020984 Wnt-4 Proteins 0.000 description 1
- 102000043366 Wnt-5a Human genes 0.000 description 1
- 102000044880 Wnt3A Human genes 0.000 description 1
- 108700013515 Wnt3A Proteins 0.000 description 1
- 210000001766 X chromosome Anatomy 0.000 description 1
- 101100485099 Xenopus laevis wnt2b-b gene Proteins 0.000 description 1
- 201000006288 alpha thalassemia Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 201000006902 exudative vitreoretinopathy Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 231100000794 masculinization Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 201000010193 neural tube defect Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 201000001937 osteoporosis-pseudoglioma syndrome Diseases 0.000 description 1
- 208000015768 polyposis Diseases 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000004263 retinal angiogenesis Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 101150068520 wnt3a gene Proteins 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261642915P | 2012-05-04 | 2012-05-04 | |
| US61/642,915 | 2012-05-04 | ||
| PCT/US2013/039484 WO2013166396A2 (en) | 2012-05-04 | 2013-05-03 | 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017173614A Division JP6378409B2 (ja) | 2012-05-04 | 2017-09-11 | １Ｈ−ピラゾロ［３，４−ｂ］ピリジンおよびそれらの治療的使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015515989A JP2015515989A (ja) | 2015-06-04 |
| JP2015515989A5 true JP2015515989A5 (enExample) | 2016-06-23 |
| JP6209593B2 JP6209593B2 (ja) | 2017-10-04 |
Family
ID=49513001
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015510483A Active JP6209593B2 (ja) | 2012-05-04 | 2013-05-03 | １Ｈ−ピラゾロ［３，４−ｂ］ピリジンおよびそれらの治療的使用 |
| JP2017173614A Expired - Fee Related JP6378409B2 (ja) | 2012-05-04 | 2017-09-11 | １Ｈ−ピラゾロ［３，４−ｂ］ピリジンおよびそれらの治療的使用 |
| JP2018139863A Pending JP2018162323A (ja) | 2012-05-04 | 2018-07-26 | １Ｈ−ピラゾロ［３，４−ｂ］ピリジンおよびそれらの治療的使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017173614A Expired - Fee Related JP6378409B2 (ja) | 2012-05-04 | 2017-09-11 | １Ｈ−ピラゾロ［３，４−ｂ］ピリジンおよびそれらの治療的使用 |
| JP2018139863A Pending JP2018162323A (ja) | 2012-05-04 | 2018-07-26 | １Ｈ−ピラゾロ［３，４−ｂ］ピリジンおよびそれらの治療的使用 |
Country Status (33)
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2835553T3 (es) | 2009-08-10 | 2021-06-22 | Biosplice Therapeutics Inc | Inhibidores de indazol de la vía de señalización de Wnt y sus usos terapéuticos |
| SMT201700581T1 (it) | 2009-12-21 | 2018-01-11 | Samumed Llc | 1h-pirazolo[3,4-b]piridine e loro usi terapeutici |
| US9442092B2 (en) | 2011-06-20 | 2016-09-13 | Kerry Lane | Methods for treatment of autism |
| HUE041576T2 (hu) | 2011-09-14 | 2019-05-28 | Samumed Llc | Indazol-3-karboxamid-származékok és alkalmazásuk Wnt/b-katenin szignalizáló útvonal inhibitorokként |
| PH12017500997A1 (en) | 2012-04-04 | 2018-02-19 | Samumed Llc | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
| SG11201407148XA (en) | 2012-05-04 | 2014-11-27 | Samumed Llc | 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof |
| US9908867B2 (en) | 2013-01-08 | 2018-03-06 | Samumed, Llc | 3-(benzoimidazol-2-yl)-indazole inhibitors of the Wnt signaling pathway and therapeutic uses thereof |
| CA3161836A1 (en) | 2013-12-11 | 2015-06-18 | Celgene Quanticel Research, Inc. | Inhibitors of lysine specific demethylase-1 |
| WO2015144290A1 (en) * | 2014-03-27 | 2015-10-01 | Merck Patent Gmbh | Pyridyl piperidines |
| WO2016040193A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof |
| WO2016040190A1 (en) * | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof |
| WO2016040184A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
| WO2016040182A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine and therapeutic uses thereof |
| WO2016040188A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
| WO2016040181A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
| WO2016040185A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof |
| WO2016040180A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
| WO2017024025A1 (en) | 2015-08-03 | 2017-02-09 | Sunil Kumar Kc | 3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| US10329309B2 (en) | 2015-08-03 | 2019-06-25 | Samumed, Llc | 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
| WO2017024026A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc | 3-(1h-indol-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof |
| US10206908B2 (en) | 2015-08-03 | 2019-02-19 | Samumed, Llc | 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
| US10604512B2 (en) | 2015-08-03 | 2020-03-31 | Samumed, Llc | 3-(1H-indol-2-yl)-1H-indazoles and therapeutic uses thereof |
| US10206909B2 (en) | 2015-08-03 | 2019-02-19 | Samumed, Llc | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
| WO2017023989A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| US10383861B2 (en) | 2015-08-03 | 2019-08-20 | Sammumed, LLC | 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
| US10231956B2 (en) | 2015-08-03 | 2019-03-19 | Samumed, Llc | 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
| US10285983B2 (en) | 2015-08-03 | 2019-05-14 | Samumed, Llc | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof |
| WO2017023980A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof |
| US10188634B2 (en) | 2015-08-03 | 2019-01-29 | Samumed, Llc | 3-(3H-imidazo[4,5-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
| US10350199B2 (en) | 2015-08-03 | 2019-07-16 | Samumed, Llc | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof |
| WO2017023993A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-indol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| US10195185B2 (en) | 2015-08-03 | 2019-02-05 | Samumed, Llc | 3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
| US10463651B2 (en) | 2015-08-03 | 2019-11-05 | Samumed, Llc | 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-indazoles and therapeutic uses thereof |
| WO2017023987A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof |
| WO2017079759A1 (en) | 2015-11-06 | 2017-05-11 | Samumed, Llc | 2-(1h-indazol-3-yl)-3h-imidazo[4,5-c]pyridines and their anti-inflammatory uses thereof |
| MY199242A (en) | 2016-06-01 | 2023-10-22 | Samumed Llc | Process for preparing n-(5-(3-(7-(3-fluorophenyl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide |
| BR112019008061A2 (pt) | 2016-10-21 | 2019-09-17 | Samumed Llc | métodos de uso de indazol-3-carboxamidas e seu uso como inibidores da via de sinalização de wnt/b-catenina |
| MA46696A (fr) | 2016-11-07 | 2019-09-11 | Samumed Llc | Formulations injectables à dose unique prêtes à l'emploi |
| US20200171024A1 (en) * | 2017-06-26 | 2020-06-04 | The Regents Of The University Of Colorado, A Body Corporate | Biomarkers for the diagnosis and treatment of fibrotic lung disease |
| WO2019108806A1 (en) * | 2017-11-29 | 2019-06-06 | Board Of Regents Of The University Of Texas System | Compositions and methods for cancer therapy |
| WO2019241540A1 (en) | 2018-06-15 | 2019-12-19 | Samumed, Llc | Indazole containing macrocycles and therapeutic uses thereof |
| EP3911317A2 (en) | 2019-01-17 | 2021-11-24 | BioSplice Therapeutics, Inc. | Methods of treating cartilage disorders through inhibition of clk and dyrk |
| WO2021168341A1 (en) | 2020-02-21 | 2021-08-26 | Samumed, Llc | Solid forms of 1-(5-(3-(7-(3-fluorophenyl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-n,n-dimethylmethanamine |
| CN111606969B (zh) * | 2020-05-13 | 2023-02-03 | 四川大学 | 一种parp1蛋白降解剂及其在抗肿瘤中的应用 |
Family Cites Families (141)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4164559A (en) | 1977-09-21 | 1979-08-14 | Cornell Research Foundation, Inc. | Collagen drug delivery device |
| ES8401486A1 (es) | 1981-11-10 | 1983-12-01 | Wellcome Found | Un procedimiento para la preparacion de nuevos derivados de imidazo (4,5-c)piridina. |
| US4474752A (en) | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
| US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
| GB9414139D0 (en) | 1994-07-13 | 1994-08-31 | Smithkline Beecham Plc | Novel compounds |
| US6440102B1 (en) | 1998-07-23 | 2002-08-27 | Durect Corporation | Fluid transfer and diagnostic system for treating the inner ear |
| DE19853299C2 (de) | 1998-11-19 | 2003-04-03 | Thomas Lenarz | Katheter zur Applikation von Medikamenten in Flüssigkeitsräumen des menschlichen Innenohrs |
| US6120484A (en) | 1999-02-17 | 2000-09-19 | Silverstein; Herbert | Otological implant for delivery of medicament and method of using same |
| HK1047582B (zh) | 1999-06-23 | 2005-03-04 | 萨诺费－阿文蒂斯德国有限公司 | 取代的苯並咪唑 |
| PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| TWI262914B (en) | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
| US6844367B1 (en) | 1999-09-17 | 2005-01-18 | Millennium Pharmaceuticals, Inc. | Benzamides and related inhibitors of factor Xa |
| US6967023B1 (en) | 2000-01-10 | 2005-11-22 | Foamix, Ltd. | Pharmaceutical and cosmetic carrier or composition for topical application |
| YU54202A (sh) | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
| US6897231B2 (en) | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| US20050009876A1 (en) | 2000-07-31 | 2005-01-13 | Bhagwat Shripad S. | Indazole compounds, compositions thereof and methods of treatment therewith |
| US7105532B2 (en) | 2000-12-19 | 2006-09-12 | Smithkline Beecham Corporation | Pyrazolo[3,4-c]pyridines as gsk-3 inhibitors |
| US20050192262A1 (en) | 2001-03-13 | 2005-09-01 | Tomas Hagstrom | Treatment of tumours |
| EP2295550A3 (en) | 2001-04-30 | 2011-12-14 | Vertex Pharmaceuticals Incorporated | Crystal structures of GSK-3beta protein and protein complexes and their use |
| US7642278B2 (en) | 2001-07-03 | 2010-01-05 | Novartis Vaccines And Diagnostics, Inc. | Indazole benzimidazole compounds |
| JP2004536113A (ja) | 2001-07-03 | 2004-12-02 | カイロン コーポレイション | チロシンキナーゼおよびセリン／スレオニンキナーゼのインヒビターとしてのインダゾールベンズイミダゾール化合物 |
| WO2003024969A1 (en) | 2001-09-14 | 2003-03-27 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| AU2002368274A1 (en) | 2001-09-13 | 2004-06-03 | Genesoft, Inc. | Methods of treating infection by drug resistant bacteria |
| US6648873B2 (en) | 2001-09-21 | 2003-11-18 | Durect Corp. | Aural catheter system including anchor balloon and balloon inflation device |
| US6897208B2 (en) | 2001-10-26 | 2005-05-24 | Aventis Pharmaceuticals Inc. | Benzimidazoles |
| FR2831536A1 (fr) | 2001-10-26 | 2003-05-02 | Aventis Pharma Sa | Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr |
| WO2003035005A2 (en) | 2001-10-26 | 2003-05-01 | University Of Connecticut | Heteroindanes: a new class of potent cannabimimetic ligands |
| IL161576A0 (en) | 2001-10-26 | 2004-09-27 | Aventis Pharma Inc | Benzimidazoles and analogues and their use as protein kinases inhibitors |
| US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| ES2281633T3 (es) | 2002-02-19 | 2007-10-01 | Pfizer Italia S.R.L. | Derivados triciclicos de pirazol, procedimiento para su preparacion y su uso como agentes antitumorales. |
| CA2476665A1 (en) | 2002-02-19 | 2003-08-28 | Pharmacia Corporation | Tricyclic pyrazole derivatives for the treatment of inflammation |
| WO2003097610A1 (en) | 2002-05-17 | 2003-11-27 | Pharmacia Italia S.P.A. | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| CN1656079A (zh) | 2002-05-31 | 2005-08-17 | 卫材株式会社 | 吡唑化合物和含有该化合物的药物组合物 |
| US7449488B2 (en) | 2002-06-04 | 2008-11-11 | Schering Corporation | Pyrazolopyrimidines as protein kinase inhibitors |
| WO2003101993A1 (en) | 2002-06-04 | 2003-12-11 | Neogenesis Pharmaceuticals, Inc. | Pyrazolo` 1,5a! pyrimidine compounds as antiviral agents |
| GB0218625D0 (en) | 2002-08-10 | 2002-09-18 | Astex Technology Ltd | Pharmaceutical compounds |
| FR2845382A1 (fr) | 2002-10-02 | 2004-04-09 | Sanofi Synthelabo | Derives d'indazolecarboxamides, leur preparation et leur utilisation en therapeutique |
| UA81453C2 (en) | 2003-02-27 | 2008-01-10 | Pyrazolopyridine derivates | |
| CN1829713A (zh) | 2003-07-30 | 2006-09-06 | 辉瑞大药厂 | 3,5二取代的吲唑化合物、药物组合物和介导或抑制细胞增殖的方法 |
| US7008953B2 (en) | 2003-07-30 | 2006-03-07 | Agouron Pharmaceuticals, Inc. | 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
| US20050090529A1 (en) | 2003-07-31 | 2005-04-28 | Pfizer Inc | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
| WO2005014554A1 (en) | 2003-08-08 | 2005-02-17 | Astex Therapeutics Limited | 1h-indazole-3-carboxamide compounds as mapkap kinase modulators |
| AU2004289539C1 (en) | 2003-11-14 | 2012-06-07 | Lorus Therapeutics Inc. | Aryl imidazoles and their use as anti-cancer agents |
| EP1532980A1 (en) | 2003-11-24 | 2005-05-25 | Novo Nordisk A/S | N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes |
| FR2864084B1 (fr) | 2003-12-17 | 2006-02-10 | Aventis Pharma Sa | Nouveaux derives organophosphores des indazoles et leur utilisation comme medicaments |
| FR2867778B1 (fr) | 2004-03-16 | 2006-06-09 | Sanofi Synthelabo | Utilisation de derives d'indazolecarboxamides pour la preparation d'un medicament destine au traitement et a la prevention du paludisme |
| WO2005092890A2 (en) | 2004-03-25 | 2005-10-06 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof |
| DE602005024677D1 (de) | 2004-04-22 | 2010-12-23 | Memory Pharm Corp | Indole, 1h-indazole, 1,2-benzisoxazole, 1,2-benzoisothiazole, deren herstellung und verwendungen |
| MXPA06013250A (es) | 2004-05-14 | 2007-02-28 | Abbott Lab | Inhibidores de quinasa como agentes terapeuticos. |
| JP2008505167A (ja) | 2004-07-05 | 2008-02-21 | アステックス、セラピューティックス、リミテッド | 医薬組成物 |
| US7452993B2 (en) | 2004-07-27 | 2008-11-18 | Sgx Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
| US7626021B2 (en) | 2004-07-27 | 2009-12-01 | Sgx Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
| WO2006024945A1 (en) | 2004-09-03 | 2006-03-09 | Pfizer Inc. | Pharmaceutical compositions comprising a cdk inhibitor |
| US7652043B2 (en) | 2004-09-29 | 2010-01-26 | The Johns Hopkins University | WNT pathway antagonists |
| WO2006054143A1 (en) | 2004-11-17 | 2006-05-26 | Pfizer Inc. | Polymorphs of {5-[3-(4,6-difluoro-1h-benzoimidazol-2-yl)-1h-indazol-5-yl]-4-methyl-pyridin-3-ylmethyl}-ethyl-amine |
| US20060116519A1 (en) | 2004-11-17 | 2006-06-01 | Agouron Pharmaceuticals, Inc. | Synthesis of 5-bromo-4-methyl-pyridin-3-ylmethyl)-ethyl-carbamic acid tert-butyl ester |
| WO2006063302A2 (en) | 2004-12-10 | 2006-06-15 | Wyeth | Variants of glycogen synthase kinase 3 and uses thereof |
| US20060142247A1 (en) | 2004-12-17 | 2006-06-29 | Guy Georges | Tricyclic heterocycles |
| PL371841A1 (pl) * | 2004-12-20 | 2006-06-26 | ADAMED Sp.z o.o. | Nowe związki pochodne kwasu 3-fenylopropionowego |
| MX2007008008A (es) | 2004-12-30 | 2007-11-12 | Astex Therapeutics Ltd | Compuestos de pirazol que modulan la actividad de las cinasas cdk, gsk y aurora. |
| JP2008537684A (ja) | 2005-01-24 | 2008-09-25 | ニューロシステック コーポレイション | 内耳およびその他の組織へ治療薬および／またはその他の薬剤を送達するための装置および方法 |
| US7541367B2 (en) * | 2005-05-31 | 2009-06-02 | Janssen Pharmaceutica, N.V. | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders |
| US8106066B2 (en) | 2005-09-23 | 2012-01-31 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof |
| UY29825A1 (es) | 2005-10-03 | 2007-05-31 | Astrazeneca Ab | Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones |
| TW200804338A (en) | 2005-11-24 | 2008-01-16 | Astrazeneca Ab | New compounds |
| KR20080106284A (ko) | 2006-03-23 | 2008-12-04 | 에프. 호프만-라 로슈 아게 | 치환된 인다졸 유도체, 이의 제조 및 약학적 제제로서의 용도 |
| US8008481B2 (en) | 2006-03-31 | 2011-08-30 | Ericsson Anna M | Indazole compounds |
| US20080153810A1 (en) | 2006-11-15 | 2008-06-26 | Forest Laboratories Holdings Limited | Indazole derivatives useful as melanin concentrating receptor ligands |
| DE602006021591D1 (de) | 2006-12-11 | 2011-06-09 | Genetics Co Inc | Aromatische 1,4-DI-Carboxylamide und deren Verwendung |
| EP1932830A1 (en) | 2006-12-11 | 2008-06-18 | The Genetics Company, Inc. | Sulfonamides and their use as a medicament |
| CA2672167C (en) | 2006-12-14 | 2016-01-26 | Bayer Schering Pharma Aktiengesellschaft | Dihydropyridine derivatives useful as protein kinase inhibitors |
| WO2008124848A1 (en) | 2007-04-10 | 2008-10-16 | Sgx Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
| US20100137394A1 (en) | 2007-04-30 | 2010-06-03 | Grenentech, Inc. | Pyrazole inhibitors of wnt signaling |
| KR101486026B1 (ko) | 2007-05-10 | 2015-01-22 | 도그우드 파마슈티컬스, 아이엔씨. | 플루오렌, 안트라센, 잔텐, 디벤조수베론 및 아크리딘의 유도체 및 이의 용도 |
| US8304408B2 (en) | 2007-05-24 | 2012-11-06 | The Regents Of The University Of California | Wnt signaling inhibitors, and methods for making and using them |
| TW200908968A (en) | 2007-05-29 | 2009-03-01 | Sgx Pharmaceuticals Inc | Substituted pyrrolopyridines and pyrazolopyridines as kinase modulators |
| US20090099062A1 (en) | 2007-05-31 | 2009-04-16 | Ethan Lee | Pyrvinium For The Treatment of Cancer |
| US8648069B2 (en) | 2007-06-08 | 2014-02-11 | Abbvie Inc. | 5-substituted indazoles as kinase inhibitors |
| CN101790526A (zh) | 2007-06-08 | 2010-07-28 | 雅培制药有限公司 | 用作激酶抑制剂的5-杂芳基取代的吲唑化合物 |
| EP2157859A4 (en) | 2007-06-19 | 2011-01-12 | Takeda Pharmaceutical | INDAZOL COMPOUNDS FOR THE ACTIVATION OF GLUCCOKINASE |
| FR2917735B1 (fr) | 2007-06-21 | 2009-09-04 | Sanofi Aventis Sa | Nouveaux indazoles substitutes, leur preparation et leur utilisation en therapeutique |
| WO2009011850A2 (en) | 2007-07-16 | 2009-01-22 | Abbott Laboratories | Novel therapeutic compounds |
| US20100190736A1 (en) | 2007-08-02 | 2010-07-29 | Nerviano Medical Sciences S.R.L. | Morpholinyl anthracycline derivative combined with protein kinase inhibitors |
| US9259399B2 (en) | 2007-11-07 | 2016-02-16 | Cornell University | Targeting CDK4 and CDK6 in cancer therapy |
| KR101061599B1 (ko) | 2008-12-05 | 2011-09-02 | 한국과학기술연구원 | 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물 |
| CN101440092B (zh) | 2008-12-25 | 2010-11-17 | 浙江大学 | 2-吲唑-4-氮杂吲哚-5-氨基衍生物及制备和应用 |
| JP2012520887A (ja) | 2009-03-18 | 2012-09-10 | シェーリング コーポレイション | ジアシルグリセロールアシルトランスフェラーゼの阻害剤としての二環式化合物 |
| JP2012521429A (ja) | 2009-03-23 | 2012-09-13 | メルク・シャープ・エンド・ドーム・コーポレイション | 疼痛治療用のｐ２ｘ３受容体アンタゴニスト |
| EP3025724B1 (en) | 2009-05-13 | 2018-07-11 | The University of North Carolina At Chapel Hill | Cyclin dependent kinase inhibitors and methods of use |
| EP2456310A4 (en) | 2009-07-23 | 2013-01-23 | Univ Vanderbilt | SUBSTITUTED BENZOIMIDAZOLSULFONAMIDES AND SUBSTITUTED INDOLSULFONAMIDES AS MGLUR4 POTENTIATORS |
| ES2835553T3 (es) | 2009-08-10 | 2021-06-22 | Biosplice Therapeutics Inc | Inhibidores de indazol de la vía de señalización de Wnt y sus usos terapéuticos |
| BR112012002942A2 (pt) | 2009-08-10 | 2015-10-13 | Epitherix Llc | indazóis como inibidores da trilha de sinalização de wnt/b-catenina e empregos terapêuticos destes. |
| WO2011050245A1 (en) | 2009-10-23 | 2011-04-28 | Yangbo Feng | Bicyclic heteroaryls as kinase inhibitors |
| JP5739448B2 (ja) | 2009-12-21 | 2015-06-24 | アレイ バイオファーマ、インコーポレイテッド | ｃＦＭＳ阻害剤としての置換Ｎ−（１Ｈ−インダゾール−４−イル）イミダゾ［１，２−ａ］ピリジン−３−カルボキサミド化合物 |
| SMT201700581T1 (it) | 2009-12-21 | 2018-01-11 | Samumed Llc | 1h-pirazolo[3,4-b]piridine e loro usi terapeutici |
| KR101792895B1 (ko) | 2010-04-06 | 2017-11-02 | 피터 맥칼룸 캔서 인스티튜트 | 방사선 보호 화합물 및 방법 |
| WO2012068589A2 (en) | 2010-11-19 | 2012-05-24 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| KR101569260B1 (ko) | 2011-01-13 | 2015-11-13 | 노파르티스 아게 | 신규 헤테로시클릭 유도체 및 신경계 장애의 치료에서의 그의 용도 |
| US8889684B2 (en) | 2011-02-02 | 2014-11-18 | Boehringer Ingelheim International Gmbh | Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors |
| WO2012129562A2 (en) | 2011-03-24 | 2012-09-27 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
| EP2694060A4 (en) | 2011-04-01 | 2014-09-10 | Univ Utah Res Found | SUBSTITUTED 3- (1H-BENZO- {D} -IMIDAZOL-2-YL-) 1H-INDAZOL ANALOGUE AS PDK1 KINASE INHIBITOR |
| RU2014105624A (ru) | 2011-08-12 | 2015-09-20 | Ф. Хоффманн-Ля Рош Аг | Соединения индазола, способ их применения и фармацевтическая композиция |
| HUE041576T2 (hu) | 2011-09-14 | 2019-05-28 | Samumed Llc | Indazol-3-karboxamid-származékok és alkalmazásuk Wnt/b-katenin szignalizáló útvonal inhibitorokként |
| US20130166396A1 (en) * | 2011-12-23 | 2013-06-27 | Horiba Jobin Yvon Sas | Process and system for adoption of a material object offered on an information network |
| EP2810198B1 (en) | 2012-01-30 | 2023-07-12 | Universiteit Gent | Anti-invasive compounds |
| PH12017500997A1 (en) | 2012-04-04 | 2018-02-19 | Samumed Llc | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
| SG11201407148XA (en) * | 2012-05-04 | 2014-11-27 | Samumed Llc | 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof |
| KR20150050527A (ko) | 2012-05-04 | 2015-05-08 | 바스프 에스이 | 치환된 피라졸-함유 화합물 및 이의 살충제로서의 용도 |
| US9056874B2 (en) | 2012-05-04 | 2015-06-16 | Novartis Ag | Complement pathway modulators and uses thereof |
| US9908867B2 (en) | 2013-01-08 | 2018-03-06 | Samumed, Llc | 3-(benzoimidazol-2-yl)-indazole inhibitors of the Wnt signaling pathway and therapeutic uses thereof |
| WO2016040185A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof |
| WO2016040182A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine and therapeutic uses thereof |
| WO2016040181A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
| WO2016040188A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
| WO2016040193A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof |
| WO2016040190A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof |
| WO2016040180A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
| WO2016040184A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
| US10463651B2 (en) | 2015-08-03 | 2019-11-05 | Samumed, Llc | 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-indazoles and therapeutic uses thereof |
| WO2017024026A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc | 3-(1h-indol-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof |
| WO2017023980A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof |
| WO2017023987A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof |
| WO2017023973A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-indol-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof |
| US10206909B2 (en) | 2015-08-03 | 2019-02-19 | Samumed, Llc | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
| US10206908B2 (en) | 2015-08-03 | 2019-02-19 | Samumed, Llc | 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
| US10329309B2 (en) | 2015-08-03 | 2019-06-25 | Samumed, Llc | 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
| US10231956B2 (en) | 2015-08-03 | 2019-03-19 | Samumed, Llc | 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
| WO2017023993A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-indol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| WO2017024013A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof |
| US10383861B2 (en) | 2015-08-03 | 2019-08-20 | Sammumed, LLC | 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
| US20180221352A1 (en) | 2015-08-03 | 2018-08-09 | Samumed, Llc | 3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof |
| US10604512B2 (en) | 2015-08-03 | 2020-03-31 | Samumed, Llc | 3-(1H-indol-2-yl)-1H-indazoles and therapeutic uses thereof |
| WO2017023989A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| US10285983B2 (en) | 2015-08-03 | 2019-05-14 | Samumed, Llc | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof |
| US10188634B2 (en) | 2015-08-03 | 2019-01-29 | Samumed, Llc | 3-(3H-imidazo[4,5-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
| US10195185B2 (en) | 2015-08-03 | 2019-02-05 | Samumed, Llc | 3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
| US10350199B2 (en) | 2015-08-03 | 2019-07-16 | Samumed, Llc | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof |
| WO2017079759A1 (en) | 2015-11-06 | 2017-05-11 | Samumed, Llc | 2-(1h-indazol-3-yl)-3h-imidazo[4,5-c]pyridines and their anti-inflammatory uses thereof |
| MY199242A (en) | 2016-06-01 | 2023-10-22 | Samumed Llc | Process for preparing n-(5-(3-(7-(3-fluorophenyl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide |
| BR112019008061A2 (pt) | 2016-10-21 | 2019-09-17 | Samumed Llc | métodos de uso de indazol-3-carboxamidas e seu uso como inibidores da via de sinalização de wnt/b-catenina |
| MA46696A (fr) | 2016-11-07 | 2019-09-11 | Samumed Llc | Formulations injectables à dose unique prêtes à l'emploi |
-
2013
- 2013-05-03 SG SG11201407148XA patent/SG11201407148XA/en unknown
- 2013-05-03 RU RU2014148773A patent/RU2689141C2/ru active
- 2013-05-03 LT LT13784942T patent/LT2770994T/lt unknown
- 2013-05-03 RS RS20191384A patent/RS59668B1/sr unknown
- 2013-05-03 EP EP19179748.9A patent/EP3593800A1/en not_active Withdrawn
- 2013-05-03 KR KR1020147027960A patent/KR102223301B1/ko active Active
- 2013-05-03 ME MEP-2019-313A patent/ME03573B/me unknown
- 2013-05-03 ES ES13784942T patent/ES2752192T3/es active Active
- 2013-05-03 CN CN201710813857.9A patent/CN107417707A/zh active Pending
- 2013-05-03 JP JP2015510483A patent/JP6209593B2/ja active Active
- 2013-05-03 PL PL13784942T patent/PL2770994T3/pl unknown
- 2013-05-03 SM SM20190618T patent/SMT201900618T1/it unknown
- 2013-05-03 PE PE2014001935A patent/PE20142365A1/es active IP Right Grant
- 2013-05-03 SG SG10201710585UA patent/SG10201710585UA/en unknown
- 2013-05-03 US US13/887,177 patent/US8883822B2/en active Active
- 2013-05-03 MX MX2014012009A patent/MX362466B/es active IP Right Grant
- 2013-05-03 BR BR112014024284-4A patent/BR112014024284B1/pt not_active IP Right Cessation
- 2013-05-03 MY MYPI2014003099A patent/MY173049A/en unknown
- 2013-05-03 AU AU2013256141A patent/AU2013256141B2/en not_active Ceased
- 2013-05-03 HU HUE13784942A patent/HUE046216T2/hu unknown
- 2013-05-03 WO PCT/US2013/039484 patent/WO2013166396A2/en not_active Ceased
- 2013-05-03 EP EP13784942.8A patent/EP2770994B1/en active Active
- 2013-05-03 SI SI201331594T patent/SI2770994T1/sl unknown
- 2013-05-03 NZ NZ629282A patent/NZ629282A/en not_active IP Right Cessation
- 2013-05-03 NZ NZ741907A patent/NZ741907A/en not_active IP Right Cessation
- 2013-05-03 MA MA37577A patent/MA37577B1/fr unknown
- 2013-05-03 HR HRP20191799TT patent/HRP20191799T1/hr unknown
- 2013-05-03 DK DK13784942T patent/DK2770994T3/da active
- 2013-05-03 PT PT137849428T patent/PT2770994T/pt unknown
- 2013-05-03 CA CA2854229A patent/CA2854229C/en active Active
- 2013-05-03 CN CN201380023502.XA patent/CN104271133B/zh active Active
- 2013-05-03 NZ NZ724837A patent/NZ724837A/en not_active IP Right Cessation
- 2013-09-05 US US14/019,147 patent/US8618128B1/en active Active
-
2014
- 2014-08-07 US US14/454,279 patent/US9012472B2/en active Active
- 2014-08-27 ZA ZA2014/06274A patent/ZA201406274B/en unknown
- 2014-10-03 CO CO14219348A patent/CO7170178A2/es unknown
- 2014-10-06 IL IL235018A patent/IL235018B/en active IP Right Grant
- 2014-10-22 PH PH12014502369A patent/PH12014502369B1/en unknown
- 2014-11-04 CL CL2014002983A patent/CL2014002983A1/es unknown
-
2015
- 2015-02-12 US US14/621,222 patent/US9233104B2/en active Active
- 2015-12-08 US US14/962,681 patent/US9586977B2/en active Active
-
2016
- 2016-08-12 AU AU2016213874A patent/AU2016213874B2/en not_active Ceased
-
2017
- 2017-01-31 US US15/420,398 patent/US10071086B2/en active Active
- 2017-09-11 JP JP2017173614A patent/JP6378409B2/ja not_active Expired - Fee Related
- 2017-09-11 PH PH12017501661A patent/PH12017501661A1/en unknown
-
2018
- 2018-02-01 IL IL257312A patent/IL257312A/en unknown
- 2018-07-11 US US16/032,905 patent/US10342788B2/en active Active
- 2018-07-19 PH PH12018501552A patent/PH12018501552A1/en unknown
- 2018-07-26 JP JP2018139863A patent/JP2018162323A/ja active Pending
-
2019
- 2019-05-29 US US16/425,700 patent/US20200155525A1/en not_active Abandoned
- 2019-09-27 ZA ZA2019/06379A patent/ZA201906379B/en unknown
- 2019-11-06 CY CY20191101168T patent/CY1122703T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014148773A (ru) | 1н-пиразоло[3,4-b]пиридины и их терапевтические применения | |
| JP2015512443A5 (enExample) | ||
| RU2014144309A (ru) | Индазольные ингибиторы сигнального пути wnt и их терапевтические применения | |
| JP2016504387A5 (enExample) | ||
| JP2014526510A5 (enExample) | ||
| JP2019514938A5 (enExample) | ||
| JP2016514100A5 (enExample) | ||
| CA2909742C (en) | Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis b | |
| US10130633B2 (en) | Compounds | |
| CN106458930B (zh) | 2-氨基嘧啶类化合物及其药物组合物和应用 | |
| JP2017508763A5 (enExample) | ||
| JP2019517487A5 (enExample) | ||
| JP2018507877A5 (enExample) | ||
| ES2911040T3 (es) | Nuevos derivados de heteroaril amida como inhibidores selectivos de histona deacetilasa 1 y 2 (HDAC1/2) | |
| RU2016141088A (ru) | 5-замещённые индазол-3-карбоксамиды и их получение и применение | |
| JP2021516674A5 (enExample) | ||
| ZA200408711B (en) | Novel thiophene amidines, composition thereof, and methods of treating complement-mediated diseases and conditions | |
| CN104822680A (zh) | 咪唑并吡啶化合物 | |
| JP2018531218A5 (enExample) | ||
| RU2016124136A (ru) | Дикетоны и гидроксикетоны в качестве активатора сигнального пути катенина | |
| RU2015140118A (ru) | γ-ДИКЕТОНЫ В КАЧЕСТВЕ АКТИВАТОРОВ WNT/β-КАТЕНИНОВОГО СИГНАЛЬНОГО ПУТИ | |
| CN106458983A (zh) | 新型化合物 | |
| BR112021007362A2 (pt) | inibidores da replicação do vírus da imunodeficiência humana | |
| JP2025505644A5 (enExample) | ||
| JP2020532550A (ja) | リゾホスファチジン酸受容体１（ｌｐａｒ１）阻害剤化合物 |